newsfilter
← Latest News
PR Newswire·

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

-- Signed strategic collaboration with Kite to co-develop and co-commercialize late-stage clinical CART-ddBCMA in multiple myeloma -- -- Presented continued robust long-term responses from CART-ddBCMA Phase 1 expansion